Microbot Medical has received 510(k) clearance for its Liberty Endovascular Robotic System, the company said Monday. The Food and Drug Administration clearance positions Microbot to start marketing ...
Microbot Medical expects to submit an application to the US FDA for its robotic surgical system by the end of 2024 after wrapping up a pivotal human clinical trial. The ACCESS-PVI study had been ...
Representing a significant advancement in healthcare, endovascular procedures performed inside blood vessels embody the intersection of medicine and technology. By addressing critical conditions such ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that it is ...
Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results